Literature DB >> 26346397

Obliteration of the Biliary System after Administration of an Oral Contrast Medium Is Probably due to Regurgitation: A Pitfall on MRCP.

Keiko Sakamoto1, Yoshinobu Shinagawa, Kimiyo Inoue, Ayako Morita, Hiroshi Urakawa, Ritsuko Fujimitsu, Kouichi Takano, Kengo Yoshimitsu.   

Abstract

PURPOSE: We retrospectively evaluated the incidence and related factors of obliteration of the lower bile duct after oral administration of contrast medium (OCM) probably resulting from its regurgitation into the biliary system (OCMRB) as observed on images of MR cholangiopancreatography (MRCP).
METHODS: We retrospectively analyzed 305 MRCP images in 278 patients obtained between February 2010 and March 2011 using negative OCM with 1.0- and 1.5-tesla clinical units. OCMRB was defined as positive when visualization of the common bile duct was clear on precontrast 2-dimensional (2D) MRCP but obliterated on postcontrast 3-dimensional (3D) MRCP. Two abdominal radiologists reviewed all images in consensus. The incidence of OCMRB was correlated to various clinicoradiological factors.
RESULTS: We observed OCMRB on 11 MRCP images in 10 patients (3.6%). Among various clinicoradiological factors, the presence of juxtapapillary diverticula, pneumobilia, and history of intervention to the papilla were suggested as significant factors related to positive OCMRB with multivariate analysis (P < 0.05).
CONCLUSION: OCMRB occurs in about 4% of the patients who undergo MRCP, typically in those with juxtapapillary diverticula, pneumobilia, and history of papillary intervention. Acquisition of MRCP images before OCM may secure visualization of the common bile duct in these patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26346397     DOI: 10.2463/mrms.2015-0044

Source DB:  PubMed          Journal:  Magn Reson Med Sci        ISSN: 1347-3182            Impact factor:   2.471


  1 in total

1.  Update Your Knowledge of Abdominal MRI: Recent Results, Which May Change Your Practice.

Authors:  Utaroh Motosugi
Journal:  Magn Reson Med Sci       Date:  2017-03-09       Impact factor: 2.471

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.